Date: 2013-01-22
Type of information: Product acquisition
Compound: Trolovol® (D-penicillamine)
Company: Imaxio (France) D&A Pharma (France)
Therapeutic area: Metabolic diseases - Rare diseases
Type agreement: product acquisition
Action mechanism:
- chelating copper agent. This chelating agent is used in the treatment of Wilson disease. Its use in Wilson disease, a rare genetic disorder of copper metabolism, relies on its binding to accumulated copper and elimination through urine.
Disease: Wilson's disease
Details:
- Imaxio, a biopharmaceutical company specialising in vaccines and genomics, has announced the acquisition of Trolovol® (Dpenicillamine), a drug for human usage indicated for Wilson\'s disease, an orphan disease affecting around 1,200 patients in France. This product previously belonged to D&A Pharma and the transaction was facilitated by CMC Consulting. This purchase will allow Imaxio to generate almost €500,000 of additional revenue in 2013, representing an increase of 20% in its turnover compared to 2012. This revenue will be re-invested in research and development activities relating to its proprietary technology for reengineering antigens, known as IMX313. This technology is used to significantly increase immunogenicity and thus the efficacy of vaccines in which it is used.
This acquisition also fits in with Imaxio’s strategy of consolidating its pharmaceutical range. The company currently distributes Spirolept®, a human vaccine indicated for preventing a professional infectious disease, which became part of Imaxio’s portfolio in 2009 following the acquisition of the company Axcell Biotechnologies. In 2012, sales of Spirolept® totalled almost €2 million and generated a turnover of €2.5 million.
In the medium term, Imaxio plans to acquire further new products and to licence its IMX313 immunogenic technology for new indications in human and animal healthcare. Imaxio was created through the merger between Diagnogene and Avidis, a spin-off from the Medical Research Council and Cambridge University in the UK. The company owns well-founded intellectual property and collaborates with numerous academic partners, including the Jenner Institute at Oxford University. In France, Imaxio already markets Spirolept®, a human vaccine indicated for preventing a professional infectious disease, and Trolovol®, an orphan drug indicated for a congenital metabolic disease.
Financial terms: Financial terms were not disclosed.
Latest news:
Is general: Yes
